Clinical Trial Search

Primary: Percentage of Participants With Clinical Procedural Success — 97.6 percentage of participants

Primary: Mean Change From Baseline in Clinic Visit Trough Evening (Pre-bronchodilator and Pre-dose) Forced Expiratory Volume in One Second (FEV1) at the End of the 24 Week…

Primary: Reduction of Medications — 5; 4 participants

Primary: Change From Baseline in Clinic Visit Trough (Pre-bronchodilator and Pre-dose) Forced Expiratory Volume in One Second (FEV1) at the End of the 24-week Treatment Period…

Primary: Ratio From Baseline of the Serum Cortisol Weighted Mean (0-24 Hours) on Day -1/1 (Baseline) and Day 42 — 0.99; 0.99; 0.96; 0.32 ratio from Baseline

Primary: Proportion of Success, Defined as Improvement of at Least 2 Grades From Baseline According to the IGA Scale Based on Facial Assessment — 16; 14.58; 11.54 Percentage of…

Primary: Depression Symptoms — 26.2; 33.1 scores on a scale — p=0.05

Primary: Toxicities Associated With Combined Radiotherapy and Erlotinib Treatments. — 15; 14; 12; 13 number of adverse events

Primary: Percentage of Participants With Dosing Frequency of Analgesics for Treating Breakthrough Pain — 50.9 Percentage of Participants

Primary: Alcohol Use — 1.37; 0.92 units on a scale

Primary: Number of Participants With the Frequency of Treatment Related Adverse Events. — 220 participants

Primary: Percentage of Participants With HBV DNA < 400 Copies/mL at Week 192 — 54.7; 75.8 percentage of participants — p=0.016

Primary: Change From Baseline in Trough (Pre-bronchodilator and Pre-dose) FEV1 on Day 7 of the Treatment Period — 0.059; 0.153; 0.198; 0.161 Liters — p=<0.001

Primary: Bleeding Frequency (Number of Total Bleeds) — 0; 54.5 Bleeds — p=<0.0001

Primary: Warming Sensation Caused by the Excipient IFF Flavor 316 282, in a Syrup Containing Paracetamol 500 mg + Pseudoephedrine 30 mg Per 30 ml Syrup — 34.2 mm